10317 results for 'namepl inhibitor'

Imagine a battlefield where the enemy doesn't just hide from soldiers—it actively sabotages their weapons. In the tumor microenvironment, cancer cells have evolved a devious strategy: they transfer th

What You Need to Know About VopratelimabWhat is Vopratelimab?Vopratelimab is an experimental monoclonal antibody that targets the Inducible T-cell CO-Stimulator (ICOS) protein, playing a

In this blog post, we will review prostate cancer markers and what you should look for in your results. Prostate antigen marker (PSA) and p63 are the most common markers found in pro

Key Facts About EtigilimabWhat is Etigilimab?Etigilimab is an anti-TIGIT monoclonal antibody being studied for its potential role in cancer immunotherapy.What role does Etigilimab play i

Key Facts About VibostolimabWhat is Vibostolimab?Vibostolimab is an anti-TIGIT monoclonal antibody developed by Merck, targeting immune checkpoint pathways to enhance anti-tumor immunity

Introduction to TNFRSF9 and Its Role in Immune ActivationTNFRSF9, also known as 4-1BB or CD137, is a co-stimulatory receptor expressed on the surface of T cells, natural killer (NK) cells

Quick Facts About IcrucumabWhat is Icrucumab?Icrucumab is a monoclonal antibody that targets vascular endothelial growth factor receptor-1 (VEGFR-1) to inhibit tumor angiogenesis.How Doe

For decades, the fight against cancer has been a relentless battle of attrition, often with treatments that harm the body as much as the disease. But a new era of precision medicine is dawning, one th

One of the greatest challenges in cancer therapy is how tumors evade immune detection. Among the mechanisms cancer cells exploit, the CD47 pathway has emerged as a major player in helping

Quick Facts About GirentuximabWhat is Girentuximab?Girentuximab is a monoclonal antibody targeting carbonic anhydrase IX (CAIX), predominantly expressed in renal cell carcinoma (RCC) cel

Myrna Hurtado, PhD Student, University of North Texas Health Science Center Advancements in modern medicine have resulted in significantly prolonging and a

Introduction to TLR4 and Cancer Toll-like receptor 4 (TLR4) is a key component of the innate immune system, primarily responsible for detecting infections and initiating inflammatory resp

For decades, cancer drug development has focused on blocking proteins—inhibiting enzymes, antagonizing receptors, disrupting signaling pathways. Yet this approach leaves a vast landscape of disease-d

Pancreatic cancer survival rates Despite recent advances in our understanding of this disease, pancreatic cancer is one of the world’s most lethal malignan

Introduction to IL-10R and Immune Suppression in CancerThe interleukin-10 receptor (IL-10R) is a key player in regulating immune responses, particularly in suppressing inflammation and ma

Introduction to CD80 and Its Role in Immune Activation CD80 is a critical immune checkpoint molecule that plays an essential role in T cell activation through co-stimulatory pathways. Exp

Introduction to TREM2 and Tumor-Associated Macrophages in CancerTREM2 (triggering receptor expressed on myeloid cells 2) is an immunoregulatory receptor primarily expressed on macrophages

Regulatory T cells (Tregs) play a crucial role in maintaining immune balance by suppressing excessive immune responses that could lead to tissue damage. However, in the context of cancer,

Quick Facts About Patritumab DeruxtecanWhat is Patritumab Deruxtecan?Patritumab Deruxtecan (HER3-DXd) is an investigational antibody-drug conjugate (ADC) targeting HER3, a receptor impli

Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest